Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Equity (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Return on Equity for 9 consecutive years, with 1.37% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 1446.0% to 1.37% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.37% through Dec 2025, up 1446.0% year-over-year, with the annual reading at 2.44% for FY2025, 28.0% up from the prior year.
  • Return on Equity for Q4 2025 was 1.37% at Rhythm Pharmaceuticals, up from 2.81% in the prior quarter.
  • The five-year high for Return on Equity was 0.15% in Q2 2021, with the low at 52.02% in Q2 2025.
  • Average Return on Equity over 5 years is 5.27%, with a median of 0.94% recorded in 2023.
  • Peak annual rise in Return on Equity hit 1446bps in 2025, while the deepest fall reached -4688bps in 2025.
  • Over 5 years, Return on Equity stood at 0.26% in 2021, then plummeted by -159bps to 0.66% in 2022, then crashed by -52bps to 1.01% in 2023, then tumbled by -1473bps to 15.82% in 2024, then soared by 91bps to 1.37% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 1.37%, 2.81%, and 52.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.